NasdaqGS:SWAV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has ShockWave Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SWAV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.8%

SWAV

1.1%

US Medical Equipment

1.0%

US Market


1 Year Return

117.2%

SWAV

15.4%

US Medical Equipment

13.6%

US Market

Return vs Industry: SWAV exceeded the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: SWAV exceeded the US Market which returned 13.6% over the past year.


Shareholder returns

SWAVIndustryMarket
7 Day9.8%1.1%1.0%
30 Day20.9%1.5%-0.4%
90 Day57.2%12.0%8.9%
1 Year117.2%117.2%16.4%15.4%16.2%13.6%
3 Yearn/a73.3%68.8%40.2%30.8%
5 Yearn/a149.6%130.6%89.6%68.2%

Price Volatility Vs. Market

How volatile is ShockWave Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ShockWave Medical undervalued compared to its fair value and its price relative to the market?

10.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SWAV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SWAV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SWAV is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SWAV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SWAV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SWAV is overvalued based on its PB Ratio (10x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is ShockWave Medical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

33.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SWAV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SWAV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SWAV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SWAV's revenue (45.1% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: SWAV's revenue (45.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SWAV is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ShockWave Medical performed over the past 5 years?

-44.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: SWAV is currently unprofitable.

Growing Profit Margin: SWAV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if SWAV's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare SWAV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SWAV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: SWAV has a negative Return on Equity (-26.32%), as it is currently unprofitable.


Next Steps

Financial Health

How is ShockWave Medical's financial position?


Financial Position Analysis

Short Term Liabilities: SWAV's short term assets ($264.3M) exceed its short term liabilities ($17.7M).

Long Term Liabilities: SWAV's short term assets ($264.3M) exceed its long term liabilities ($24.2M).


Debt to Equity History and Analysis

Debt Level: SWAV's debt to equity ratio (6.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if SWAV's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SWAV has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SWAV has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 31.8% each year.


Next Steps

Dividend

What is ShockWave Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SWAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SWAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SWAV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SWAV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SWAV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Doug Godshall (55 yo)

3.33yrs

Tenure

US$2,208,317

Compensation

Mr. Douglas E. Godshall, also known as Doug, M.B.A., has been the Chief Executive Officer and President of Shockwave Medical, Inc. since May 10, 2017. Mr. Godshall has been an Executive Director at HeartWa ...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD2.21M) is below average for companies of similar size in the US market ($USD5.70M).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Godshall
President3.33yrsUS$2.21m0.29%
$ 7.1m
Daniel Puckett
CFO & Secretary4.42yrsUS$1.24m0.11%
$ 2.7m
Isaac Zacharias
Chief Commercial Officer1.83yrsUS$658.55k0.17%
$ 4.2m
Daniel Hawkins
Founder and Senior Advisor11.67yrsno datano data
John Adams
Co-Founder and Technical Advisor11.67yrsno datano data
Mike Maszy
Vice President of Operations1.83yrsno datano data
Debbie Kaster
Head of Investor Relations0.17yrno datano data
Hajime Tada
General Counsel & Secretary1.25yrsno datano data
Rob Williamson
Vice President of Sales3.33yrsno datano data
Robert Fletcher
Vice President of Marketing4.17yrsno datano data
Cathy Harnett
Director of Human Resources2.25yrsno datano data
Keith Dawkins
Chief Medical Officer1.33yrsno datano data

2.8yrs

Average Tenure

55.5yo

Average Age

Experienced Management: SWAV's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Douglas Godshall
President3.33yrsUS$2.21m0.29%
$ 7.1m
Antoine Papiernik-Berkhauer
Independent Director7.17yrsUS$185.25k0.0079%
$ 195.3k
Frederic Moll
Independent Director9.67yrsUS$185.00k0.82%
$ 20.2m
Charles Larkin
Independent Chairman of the Board1.67yrsUS$161.15k0.0079%
$ 195.3k
Laura Francis
Independent Director1.67yrsUS$122.42k0.0079%
$ 195.3k
Maria Sainz
Director0.17yrno datano data
Colin Cahill
Independent Director5.33yrsUS$189.17k0.0079%
$ 195.3k
F. Watkins
Independent Director7.67yrsUS$188.33k0.34%
$ 8.3m

4.3yrs

Average Tenure

54.5yo

Average Age

Experienced Board: SWAV's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.3%.


Top Shareholders

Company Information

ShockWave Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ShockWave Medical, Inc.
  • Ticker: SWAV
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.460b
  • Shares outstanding: 34.00m
  • Website: https://www.shockwavemedical.com

Number of Employees


Location

  • ShockWave Medical, Inc.
  • 5403 Betsy Ross Drive
  • Santa Clara
  • California
  • 95054
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SWAVNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2019
36MDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2019

Biography

ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and he ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 06:41
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.